BioSpace News Archive

Transparency Market Research has published a new report titled, “Medial Robotic Systems Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2017–2025”. According to the report, the global medical robotic systems market was valued at US$ 6,458.0 Mn in 2017 and is projected to expand at a CAGR of 18.9% from 2018 to 2026.

Nucleic acid isolation, or DNA isolation, is a procedure that involves the distillation of a given DNA sample using a number of combined chemical and physical processes.

NGS is the term which is used to describe a number of different modern sequencing technologies and is also known as high throughput sequencing.

JEOL Ltd. announces the release of a new Schottky field emission scanning electron microscope, JSM-IT800 in May 2020.

4DMedical, an Australian medical technology company specializing in medical imaging innovation software, announced it has received clearance from the U.S. Food & Drug Administration to market its XV Technology™, a patented four-dimensional lung imaging process that rapidly and automatically analyses any functional lung impairment from a single X-ray.

Mesoblast Limited announced that clinical outcomes of its allogeneic mesenchymal stem cell medicine RYONCIL™ in children and adults with steroid-refractory acute graft versus host disease have been published in three peer-reviewed articles and an accompanying editorial in the May issue of Biology of Blood and Marrow Transplantation, the official publication of the American Society for Transplantation and Cellular Therapy.

SaNOtize Research and Development Corporation (“SaNOtize” or “the company”) today announced it enrolled its first participant on May 12, 2020 in a multi-centre Phase II trial of its Nitric Oxide Releasing Solution (NORS TM ) for the prevention and early treatment of COVID-19. The Company is continuing enrolment in British Columb

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “ Company ” or “ Algernon ”) a clinical stage pharmaceutical development company, is pleased to announce that it has submitted an Investigational New Drug (IND) application with the U.S. FDA for its planned multinational Phase 2b/3 study of its re-purposed drug NP-120 (Ifenprodil) as a potential therapeutic treatment for patients with COVID-19. Ifenprodil

Supports advancement of its immune-oncology programs Enables portfolio expansion/product acquisitions Intention to proceed with consolidation (reverse stock split)

According to the report, the global kinase inhibitors market was valued at ~US$ 46.4 Bn in 2018 and is projected to expand at a CAGR of ~4% from 2019 to 2027.